NEW YORK (GenomeWeb News) – Shares of CombiMatrix rose as much as 25 percent today after the company said that it expects to report record volumes of prenatal testing for the first quarter.

The Irvine, Calif.-based firm said today that for the three months ended March 31, billable prenatal tests were up 124 percent year over year in preliminary results. Investors responded by driving shares up as high as $4.62, up from Wednesday's closing price of $3.46.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.